Corcept Resubmits Relacorilant
Corcept Therapeutics is resubmitting its application for relacorilant to the FDA. The move may impact the company's stock price.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.